Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancerS Novello, B Besse, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2009
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patientsF Cappuzzo, G Tallini, G Finocchiaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2008
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsF Cappuzzo, P A Jänne, M Skokan, et al.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2007
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patientsF Cappuzzo, G Finocchiaro, E Rossi, et al.
British Journal of Cancer|November 17, 2005
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patientsF Cappuzzo, L Toschi, I Domenichini, et al.
British Journal of Cancer|June 11, 2008
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trialsG L Ceresoli, B Castagneto, P A Zucali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancerG V Scagliotti, I Bondarenko, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2007
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinibF R Hirsch, M Varella-Garcia, F Cappuzzo, et al.
Pageof 9